Hamilton Thorne (TSX:HTL) - Stock Price, News & Analysis

HTL Stock Overview

Develops, manufactures, and sells precision instruments, laboratory equipment, consumables, software, and services for the assisted reproductive technologies (ART), research, and cell biology markets. More details

HTL fundamental analysis
Snowflake Score
Valuation	3/6
Future Growth	4/6
Past Performance	0/6
Financial Health	4/6
Dividends	0/6

Rewards

Trading at 50.9% below our estimate of its fair value

Earnings are forecast to grow 161.56% per year

Risk Analysis

No risks detected for HTL from our risk checks.

Hamilton Thorne Ltd. Competitors

Opsens

TSX:OPS

CA$335.8m

Profound Medical

TSX:PRN

CA$267.8m

Aurora Spine

TSXV:ASG

CA$33.3m

Conavi Medical

TSXV:CNVI

CA$38.1m

Price History & Performance

Summary of all time highs, changes and price drops for Hamilton Thorne
Historical stock prices
Current Share Price	CA$2.25
52 Week High	CA$2.25
52 Week Low	CA$1.14
Beta	0.41
11 Month Change	0.90%
3 Month Change	7.66%
1 Year Change	80.00%
33 Year Change	4.65%
5 Year Change	114.29%
Change since IPO	492.11%

A Piece Of The Puzzle Missing From Hamilton Thorne Ltd.'s (TSE:HTL) 47% Share Price Climb

Jul 29

Recent updates

A Piece Of The Puzzle Missing From Hamilton Thorne Ltd.'s (TSE:HTL) 47% Share Price Climb

Jul 29

These 4 Measures Indicate That Hamilton Thorne (CVE:HTL) Is Using Debt Reasonably Well

Aug 15

Announcing: Hamilton Thorne (CVE:HTL) Stock Soared An Exciting 590% In The Last Five Years

Jan 19

Are Insiders Selling Hamilton Thorne Ltd. (CVE:HTL) Stock?

Jan 06

What Did Hamilton Thorne's (CVE:HTL) CEO Take Home Last Year?

Dec 24

We Think Hamilton Thorne (CVE:HTL) Can Stay On Top Of Its Debt

Dec 12

Is It Time To Consider Buying Hamilton Thorne Ltd. (CVE:HTL)?

Nov 30

A Look At The Fair Value Of Hamilton Thorne Ltd. (CVE:HTL)

Nov 17

Shareholder Returns

	HTL	CA Medical Equipment	CA Market
7D	0.4%	6.7%	0.4%
1Y	80.0%	3.7%	21.4%

Return vs Industry: HTL exceeded the Canadian Medical Equipment industry which returned 3.7% over the past year.

Return vs Market: HTL exceeded the Canadian Market which returned 21.4% over the past year.

Price Volatility

Is HTL's price volatile compared to industry and market?
HTL volatility
HTL Average Weekly Movement	1.6%
Medical Equipment Industry Average Movement	13.7%
Market Average Movement	8.3%
10% most volatile stocks in CA Market	17.7%
10% least volatile stocks in CA Market	2.9%

Stable Share Price: HTL has not had significant price volatility in the past 3 months compared to the Canadian market.

Volatility Over Time: HTL's weekly volatility has decreased from 8% to 2% over the past year.

About the Company

Founded	Employees	CEO	Website
n/a	n/a	Kate Torchilin	www.hamiltonthorne.ltd

Hamilton Thorne Ltd. develops, manufactures, and sells precision instruments, laboratory equipment, consumables, software, and services for the assisted reproductive technologies (ART), research, and cell biology markets. The company offers precision laser systems and imaging systems for biology markets. It also provides test laboratory and endotoxin testing services, as well as sperm assays, including Sperm Motility Index and Sperm Penetration; and fresh and cryopreserved mouse embryos supply, and technician training and proficiency testing services.

Hamilton Thorne Ltd. Fundamentals Summary

How do Hamilton Thorne's earnings and revenue compare to its market cap?
HTL fundamental statistics
Market cap	CA$346.28m
Earnings (TTM)	-CA$2.92m
Revenue (TTM)	CA$106.54m

3.3x

P/S Ratio

-118.6x

P/E Ratio

Is HTL overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
HTL income statement (TTM)
Revenue	US$76.30m
Cost of Revenue	US$37.45m
Gross Profit	US$38.85m
Other Expenses	US$40.94m
Earnings	-US$2.09m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-0.014
Gross Margin	50.92%
Net Profit Margin	-2.74%
Debt/Equity Ratio	29.9%

How did HTL perform over the long term?

See historical performance and comparison

HTL Stock Overview

Rewards

Risk Analysis

Hamilton Thorne Ltd. Competitors

TSX:OPS

CA$335.8m

TSX:PRN

CA$267.8m

TSXV:ASG

CA$33.3m

TSXV:CNVI

CA$38.1m

Price History & Performance

Recent News & Updates

Third quarter 2024 earnings: EPS misses analyst expectations

Second quarter 2024 earnings released: US$0.003 loss per share (vs US$0.003 loss in 2Q 2023)

Hamilton Thorne Ltd. to Report Q2, 2024 Results on Aug 14, 2024

A Piece Of The Puzzle Missing From Hamilton Thorne Ltd.'s (TSE:HTL) 47% Share Price Climb

New minor risk - Share price stability

Recent updates

Third quarter 2024 earnings: EPS misses analyst expectations

Second quarter 2024 earnings released: US$0.003 loss per share (vs US$0.003 loss in 2Q 2023)

Hamilton Thorne Ltd. to Report Q2, 2024 Results on Aug 14, 2024

A Piece Of The Puzzle Missing From Hamilton Thorne Ltd.'s (TSE:HTL) 47% Share Price Climb

New minor risk - Share price stability

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Hamilton Thorne Ltd. to Report Q1, 2024 Results on May 14, 2024

Hamilton Thorne Ltd., Annual General Meeting, Jun 11, 2024

Full year 2023 earnings released: US$0.004 loss per share (vs US$0.013 profit in FY 2022)

Hamilton Thorne Ltd. Provides Earnings Guidance for the First Quarter 2024 and Full Twelve Months of 2024

Hamilton Thorne Ltd. to Report Q4, 2023 Results on Mar 27, 2024

Hamilton Thorne Ltd. Announces CEO Changes, Effective January 15, 2024

New major risk - Revenue and earnings growth

Hamilton Thorne Ltd. to Report Q3, 2023 Results on Nov 13, 2023

Hamilton Thorne Ltd. (TSX:HTL) agreed to acquire Gynetics Medical Products N.V. for an enterprise value of €18.3 million.

Consensus EPS estimates increase by 80%

New minor risk - Shareholder dilution

Hamilton Thorne Ltd.(TSXV:HTL) dropped from S&P/TSX Venture Composite Index

Consensus EPS estimates fall by 80%

Second quarter 2023 earnings released: US$0.003 loss per share (vs US$0.002 profit in 2Q 2022)

These 4 Measures Indicate That Hamilton Thorne (CVE:HTL) Is Using Debt Reasonably Well

Hamilton Thorne Ltd. to Report Q2, 2023 Results on Aug 17, 2023

Consensus EPS estimates fall by 50%

First quarter 2023 earnings released: EPS: US$0.001 (vs US$0.004 in 1Q 2022)

Hamilton Thorne Ltd. to Report Q1, 2023 Results on May 15, 2023

Chair, President & CEO exercised options to buy CA$102k worth of stock.

Chair, President & CEO recently sold CA$101k worth of stock

Full year 2022 earnings: EPS misses analyst expectations

Now 22% undervalued after recent price drop

Now 20% undervalued

Consensus EPS estimates increase by 17%

Now 20% undervalued after recent price drop

Hamilton Thorne Ltd. Announces Passing of Diarmaid Douglas-Hamilton, Cofounder and Chief Technology Officer

Now 21% undervalued after recent price drop

Hamilton Thorne Ltd. (TSXV:HTL) agreed to acquire Microptic, S.L.

Consensus EPS estimates fall by 33%

Hamilton Thorne Ltd. Provides Sales Guidance for the Year 2022

Third quarter 2022 earnings released: EPS: US$0.001 (vs US$0.002 in 3Q 2021)

High number of new directors

Hamilton Thorne Ltd. to Report Nine Months, 2022 Results on Nov 22, 2022

Consensus EPS estimates fall by 23%

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Hamilton Thorne Ltd. to Report Q2, 2022 Results on Aug 23, 2022

Hamilton Thorne Ltd. Announces CFO Changes

Chair, President exercised options to buy CA$86k worth of stock.

Chair, President exercised options to buy CA$886k worth of stock.

Consensus EPS estimates fall by 20%

At CA$1.40, Is Hamilton Thorne Ltd. (CVE:HTL) Worth Looking At Closely?

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Hamilton Thorne Ltd. to Report Q1, 2022 Results on May 19, 2022

Investor sentiment deteriorated over the past week

High number of new directors

Hamilton Thorne Ltd., Annual General Meeting, Jun 14, 2022

Full year 2021 earnings: EPS exceeds analyst expectations

Chair, President exercised options to buy CA$293k worth of stock.

Hamilton Thorne Ltd. to Report Q4, 2021 Results on Apr 07, 2022

Is Hamilton Thorne (CVE:HTL) Using Too Much Debt?

High number of new directors

President recently bought CA$75k worth of stock

President recently sold CA$635k worth of stock